clinical trial · NCT06983028
Atacicept in Multiple Glomerular Diseases
pMNIgANNephrotic SyndromeMCDFSGSAtacicept
brief summary
The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.
started
Jul 7, 2025
primary completion
Nov 1, 2027
completion
Nov 1, 2027
last updated
Jan 20, 2026
detailed description
The study will assess the safety and efficacy of atacicept in multiple autoimmune glomerular diseases including IgAN (IgA Nephropathy), pMN (Primary Membranous Nephropathy) and MCD/FSGS (Minimal Change Disease/Focal Segmental Glomerulosclerosis) in participants ages 10 and above with weekly SC injections.
official title
A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol